Challenges and opportunities of next generation therapeutics: A compound management perspective

In recent years, pharmaceutical research has increased its interest in novel drug modalities beyond small molecules to overcome therapeutic limitations and find more effective cures. Compound Management teams globally are adapting their processes and equipment to handle such "new modalities" with the same quality and speed as small molecule research. Here, we share our approach in supporting next-generation therapeutics by introducing solutions for multi-solvent workflows in Compound Management at AstraZeneca. From sample submission to assay-ready plate generation, we describe the challenges faced and process improvements introduced so far. Collaborating with our business partners, we are pioneering new best practices and laying solid foundations for future research to bring new efficacious drugs into the clinics.

Authors

Institutions

Publication Details

Journal
SLAS TECHNOLOGY
Published
2024-10-12
DOI
https://doi.org/10.1016/j.slast.2024.100201
Primary Topic
Protein Degradation and Inhibitors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Challenges and opportunities of next generation therapeutics: A compound management perspective

Silvio Di Castro, Martin Svensson
SLAS TECHNOLOGY
Protein Degradation and Inhibitors
article

Challenges and opportunities of next generation therapeutics: A compound management perspective

Silvio Di Castro, Martin Svensson
article en

Abstract

In recent years, pharmaceutical research has increased its interest in novel drug modalities beyond small molecules to overcome therapeutic limitations and find more effective cures. Compound Management teams globally are adapting their processes and equipment to handle such "new modalities" with the same quality and speed as small molecule research. Here, we share our approach in supporting next-generation therapeutics by introducing solutions for multi-solvent workflows in Compound Management at AstraZeneca. From sample submission to assay-ready plate generation, we describe the challenges faced and process improvements introduced so far. Collaborating with our business partners, we are pioneering new best practices and laying solid foundations for future research to bring new efficacious drugs into the clinics.

SLAS TECHNOLOGYVol. 29(6)
AstraZeneca (Netherlands) (NL), AstraZeneca (Sweden) (SE)
Openalex Percentile: Top 84%
Protein Degradation and Inhibitors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Challenges and opportunities of next generation therapeutics: A compound management perspective — Silvio Di Castro, Martin Svensson · SLAS TECHNOLOGY (2024) | TGRS Research Map | TGRS